Patents by Inventor Thomas Primiano
Thomas Primiano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10111898Abstract: Disclosed herein are oligonucleotide sequences that generate innate immunity in cells within tumors upon its delivery into tumors. In certain embodiments, these oligonucleotides are specifically delivered into tumors through nanoparticles displaying targeting peptides that confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: GrantFiled: June 15, 2015Date of Patent: October 30, 2018Assignee: PeptiMed, Inc.Inventors: Thomas Primiano, Bey-Dih Chang
-
Publication number: 20160362693Abstract: This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.Type: ApplicationFiled: January 22, 2016Publication date: December 15, 2016Inventors: Thomas Primiano, Lonnie Bookbinder, Bey-Dih Chang, Jeremy Heidel
-
Patent number: 9358308Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: GrantFiled: February 7, 2014Date of Patent: June 7, 2016Assignee: NanoOncology, Inc.Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
-
Publication number: 20160058784Abstract: Disclosed herein are oligonucleotide sequences that generate innate immunity in cells within tumors upon its delivery into tumors. In certain embodiments, these oligonucleotides are specifically delivered into tumors through nanoparticles displaying targeting peptides that confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: ApplicationFiled: June 15, 2015Publication date: March 3, 2016Inventors: Thomas Primiano, II, Bey-Dih Chang
-
Patent number: 9273316Abstract: This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.Type: GrantFiled: May 23, 2011Date of Patent: March 1, 2016Assignee: PeptiMed, Inc.Inventors: Thomas Primiano, Lonnie Bookbinder, Bey-Dih Chang, Jeremy Heidel
-
Publication number: 20140220045Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: ApplicationFiled: February 7, 2014Publication date: August 7, 2014Applicant: NANOONCOLOGY, INC.Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
-
Patent number: 8680045Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: GrantFiled: November 1, 2011Date of Patent: March 25, 2014Assignee: PeptiMed, Inc.Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
-
Publication number: 20120208742Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: ApplicationFiled: November 1, 2011Publication date: August 16, 2012Applicant: NANOONCOLOGYInventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
-
Publication number: 20110293698Abstract: This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.Type: ApplicationFiled: May 23, 2011Publication date: December 1, 2011Applicant: NanoOncology, Inc.Inventors: Thomas Primiano, Lonnie Bookbinder, Bey-Dih Chang, Jeremy Heidel
-
Patent number: 7851219Abstract: Disclosed herein are compositions and methods for increasing protein production from a cell culture. By switching the cells from a replicative to a productive state (RP switch), protein biosynthesis is extended. The productive state is a pseudo-senescent state. This pseudo-senescent state can be induced by transforming the cells with a vector expressing a cell cycle inhibitor. Expression of the cell cycle inhibitor within the cell, because it does not cause cell death, allows for cells to be maintained in culture for longer periods. The invention allows for controlled enhanced protein biosynthetic productivity of cell lines for commercial and research purposes.Type: GrantFiled: June 10, 2008Date of Patent: December 14, 2010Assignee: CDI BioscienceInventors: Todd Bucciarelli, Victor Levenson, Thomas Primiano
-
Publication number: 20100075416Abstract: Disclosed is a growth factor supplement for stem cell culture media, stem cell culture media supplemented with the growth factor supplement, and methods for growing and maintaining stem cells in culture. The invention particularly relates to human stem cells, more particularly human embryonic stem cells, neonatal stem cells, adult stem cells, and IPS cells.Type: ApplicationFiled: December 23, 2008Publication date: March 25, 2010Applicant: SHILOH LABORATORIES, INC.Inventor: Thomas Primiano
-
Publication number: 20090142828Abstract: Disclosed herein are compositions and methods for increasing protein production from a cell culture. By switching the cells from a replicative to a productive state (RP switch), protein biosynthesis is extended. The productive state is a pseudo-senescent state. This pseudo-senescent state can be induced by transforming the cells with a vector expressing a cell cycle inhibitor. Expression of the cell cycle inhibitor within the cell, because it does not cause cell death, allows for cells to be maintained in culture for longer periods. The invention allows for controlled enhanced protein biosynthetic productivity of cell lines for commercial and research purposes.Type: ApplicationFiled: June 10, 2008Publication date: June 4, 2009Applicant: CLONEX DEVELOPMENT, INC.Inventors: Todd Bucciarelli, Victor Levenson, Thomas Primiano
-
Publication number: 20090142839Abstract: The present invention provides stem cell feeder layer cell lines that contain are readily triggered to differentiation. The expression vector encodes the senescence-triggering factors (STFs) consisting of Cip/Kip, INK4A, Cy protein or ankyrin-binding protein motifs. Each expression vector also contains an inducible transcription regulation element for conditional expression of the STFs.Type: ApplicationFiled: May 5, 2008Publication date: June 4, 2009Applicant: SHILOH LABORATORIES, INC.Inventor: Thomas Primiano
-
Publication number: 20080241924Abstract: This invention provides methods and reagents for inducing cell death in tumor cells. The invention provides said reagents relating to inducing tumor cell death that are antibodies to a specific target, L1CAM, and methods for using said antibodies for inducing cell death. Pharmaceutical compositions of the L1CAM antibodies for use in the practice of the methods of the invention are also disclosed.Type: ApplicationFiled: June 13, 2008Publication date: October 2, 2008Applicant: Board of Trustees of the University of IllinoisInventors: Thomas Primiano, Igor B. Roninson
-
Patent number: 7384776Abstract: Disclosed herein are compositions and methods for increasing protein production from a cell culture. By switching the cells from a replicative to a productive state (RP switch), protein biosynthesis is extended. The productive state is a pseudo-senescent state. This pseudo-senescent state can be induced by transforming the cells with a vector expressing a cell cycle inhibitor. Expression of the cell cycle inhibitor within the cell, because it does not cause cell death, allows for cells to be maintained in culture for longer periods. The invention allows for controlled enhanced protein biosynthetic productivity of cell lines for commercial and research purposes.Type: GrantFiled: August 22, 2003Date of Patent: June 10, 2008Assignee: Clonex Development, Inc.Inventors: Todd Bucciarelli, Victor Levenson, Thomas Primiano
-
Patent number: 7235403Abstract: The invention provides methods and reagents for identifying mammalian genes necessary for tumor cell growth as targets for developing drugs that inhibit expression of said genes and inhibit tumor cell growth thereby.Type: GrantFiled: July 19, 2002Date of Patent: June 26, 2007Assignee: Board of Trustees of the University of IllinoisInventors: Thomas Primiano, Bey-Dih Chang, Igor B. Roninson
-
Publication number: 20060051861Abstract: The present invention provides cell lines useful in the production proteins and peptides. The cell lines contain recombinant expression constructs. The recombinant expression construct encodes the STPs consisting of the Cy protein motif and/or an ankyrin-binding protein motif. Each recombinant expression construct also contains an inducible transcription regulation element having for conditional expression of the senescence-triggering factors (STPs).Type: ApplicationFiled: December 14, 2004Publication date: March 9, 2006Applicant: Clonex Development, Inc.Inventor: Thomas Primiano
-
Publication number: 20050074856Abstract: Disclosed herein are compositions and methods for increasing protein production from a cell culture. By switching the cells from a replicative to a productive state (RP switch), protein biosynthesis is extended. The productive state is a pseudo-senescent state. This pseudo-senescent state can be induced by transforming the cells with a vector expressing a cell cycle inhibitor. Expression of the cell cycle inhibitor within the cell, because it does not cause cell death, allows for cells to be maintained in culture for longer periods. The invention allows for controlled enhanced protein biosynthetic productivity of cell lines for commercial and research purposes.Type: ApplicationFiled: August 22, 2003Publication date: April 7, 2005Inventors: Todd Bucciarelli, Victor Levenson, Thomas Primiano
-
Publication number: 20040115206Abstract: This invention provides methods and reagents for inducing cell death in tumor cells. The invention provides said reagents relating to inducing tumor cell death that are antibodies to a specific target, L1CAM, and methods for using said antibodies for inducing cell death. Pharmaceutical compositions of the L1CAM antibodies for use in the practice of the methods of the invention are also disclosed.Type: ApplicationFiled: October 23, 2003Publication date: June 17, 2004Inventors: Thomas Primiano, Igor B. Roninson
-
Patent number: 6635448Abstract: Disclosed herein are compositions and methods for increasing protein production from a cell culture. By switching the cells from a replicative to a productive state (RP switch), protein biosynthesis is extended. The productive state is a pseudo-senescent state. This pseudo-senescent state can be induced by transforming the cells with a vector expressing a cell cycle inhibitor. Expression of the cell cycle inhibitor within the cell, because it does not cause cell death, allows for cells to be maintained in culture for longer periods. The invention allows for controlled enhanced protein biosynthetic productivity of cell lines for commercial and research purposes.Type: GrantFiled: August 21, 2001Date of Patent: October 21, 2003Assignee: ClonexDevelopment, Inc.Inventors: Todd Bucciarelli, Victor Levenson, Thomas Primiano